Pfizer Inc. $PFE Shares Acquired by Deutsche Bank AG

Deutsche Bank AG increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 0.2% during the 2nd quarter, Holdings Channel.com reports. The fund owned 31,492,018 shares of the biopharmaceutical company’s stock after purchasing an additional 63,031 shares during the quarter. Deutsche Bank AG’s holdings in Pfizer were worth $758,328,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of PFE. Handelsbanken Fonder AB raised its stake in shares of Pfizer by 10.4% during the second quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock worth $59,295,000 after purchasing an additional 232,528 shares during the last quarter. Russell Investments Group Ltd. grew its position in Pfizer by 15.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company’s stock valued at $132,365,000 after buying an additional 745,213 shares during the last quarter. Vanguard Group Inc. increased its stake in Pfizer by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after buying an additional 7,031,162 shares during the period. Leuthold Group LLC purchased a new position in Pfizer during the 2nd quarter worth $4,887,000. Finally, North Dakota State Investment Board purchased a new position in Pfizer during the 4th quarter worth $5,348,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on PFE. UBS Group reaffirmed a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a report on Wednesday, May 27th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research report on Monday, July 6th. Wolfe Research reissued an “underperform” rating and issued a $26.00 target price on shares of Pfizer in a report on Thursday, May 14th. HSBC lowered shares of Pfizer from a “buy” rating to a “hold” rating and decreased their target price for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. Finally, Bank of America dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $28.28.

Pfizer Price Performance

PFE stock opened at $28.00 on Friday. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 12-month low of $23.58 and a 12-month high of $28.75. The stock has a 50-day moving average price of $25.30 and a two-hundred day moving average price of $26.25. The company has a market cap of $159.59 billion, a PE ratio of 36.84 and a beta of 0.34.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The business had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.1%. Pfizer’s dividend payout ratio is presently 226.32%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer completed a Phase 1/2 study of PF-07868489, an experimental treatment for pulmonary arterial hypertension. The milestone supports early-stage pipeline progress, though additional clinical testing will be needed before any potential commercialization. Pfizer’s PF-07868489 PAH Study Reaches Completion
• Positive Sentiment: Several additional clinical updates highlighted progress across Pfizer’s development portfolio: completion of a Phase 1 atirmociclib study, completion of a drug-interaction study for PF-07248144, and a new Phase 1 liver study for atirmociclib. These milestones may reinforce confidence in Pfizer’s ability to replenish revenue as older products face competition. Atirmociclib Study Update PF-07248144 Study Update
• Positive Sentiment: Pfizer is also expanding real-world evidence efforts for prostate cancer therapies, Ibrance in advanced breast cancer, and a migraine treatment study in India. These studies could support broader use and strengthen commercial evidence for existing medicines. Pfizer Real-World Prostate Cancer Study
• Positive Sentiment: Investor-oriented coverage remains constructive, citing Pfizer’s roughly 19% year-to-date gain, attractive dividend yield, and reported hedge-fund buying. The stock’s move toward its 52-week high suggests improving sentiment. Hedge Funds Buying Pfizer
• Neutral Sentiment: Unusually large options activity may increase short-term trading interest, but it does not establish a clear fundamental direction for PFE. Pfizer Options Trading
• Negative Sentiment: Coverage of settlements involving thousands of Depo-Provera lawsuits raises concerns about potential legal costs and ongoing liability. Analysts also continue to weigh whether new drugs and acquisitions can offset revenue losses from expiring patents. Pfizer Legal Claims

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.